Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 4Lymphoma, Large B-Cell, Diffuse 2Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Hodgkin Disease 1Hand-Foot Syndrome 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cancer Related Fatigue 1Breast Neoplasms, Male 1

Interventions

Cyclophosphamide 26fludarabine 16Etoposide 15Melphalan 13romidepsin 12Gemcitabine 11Whole-Body Irradiation 10Vincristine 10Peripheral Blood Stem Cell Transplantation 10Doxorubicin 10fludarabine phosphate 9Rituximab 9Lenalidomide 9Cytarabine 9Busulfan 9pembrolizumab 8Prednisone 8Mycophenolic Acid 8Granulocyte Colony-Stimulating Factor 8Bortezomib 8Filgrastim 7Carmustine 7Brentuximab Vedotin 7Biopsy 7duvelisib 6Tacrolimus 6Specimen Handling 6Dexamethasone 6Bendamustine Hydrochloride 6ruxolitinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, T-Cell × Pyridoxine × Clear all
NCT02961816 2017-04-21

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Lymphoma

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡